BACKGROUND
Soy isoflavones are being evaluated as chemopreventive agents for breast and other cancers.
OBJECTIVE
The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, daidzein, and glycitein in postmenopausal